IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

IBD [Ulcerative Colitis & Crohn’s Disease] Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Corticosteroids, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Outlook 2031

  • The global IBD (ulcerative colitis & Cohn's disease) treatment market was valued at US$ 17.3 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.8% from 2022 to 2031
  • The global IBD (ulcerative colitis & Cohn's disease) treatment market is anticipated to reach more than US$ 34.22 Bn by 2031

Analysts’ Viewpoint on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Scenario

Rise in inflammatory bowel disease (IBD) patient pool, approval of new biologic drugs for IBD, novel drugs pipeline, and increase in demand for application of IBD treatment in developing countries are anticipated to propel the global IBD (ulcerative colitis and Crohn’s disease) treatment market. However, high costs could hamper the sales of therapeutics. Reimbursement plans introduced by the leading players to cushion healthcare expenditure will lead to positive sentiment among patients toward effective treatment. Growth in investments in TNF inhibitors is expected to help achieve high ROI, as physicians tend to prescribe these drugs for the treatment of moderate to severe ulcerative colitis. Furthermore, development of anti-adhesion molecules is likely to boost the adoption of integrin antagonists.

Ibd Treatment Market

IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Introduction

Rise in prevalence of inflammatory bowel disease (IBD) across the globe is driving the global IBD (Ulcerative Colitis & Crohn’s Disease) treatment market. IBD is a group of gastrointestinal inflammatory diseases that primarily comprises ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Ulcerative colitis disease mostly affects the inner lining of large intestines and causes inflammation and sores in the colon and rectum. Ulcerative colitis is a more commonly observed disease than Crohn’s disease. It can affect any part of the gastrointestinal tract, starting from the mouth to the small intestine and anus. Common symptoms of IBD include chronic pain and cramps in the abdomen, persistent diarrhea, occasional rectal bleeding, and fever. The exact cause of inflammatory bowel disease is not well understood, and high prevalence and incidence rates of these diseases have been observed in developed countries.

Innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are the factors driving the global IBD treatment market. Growth in sales of IBD drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars – adalimumab and infliximab – for the treatment of Ulcerative Colitis. Biopharmaceutical companies have made significant investments in R&D activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize during the forecast period. Furthermore, high prevalence and incidence of IBD in countries in the West is anticipated to augment the global market. According to a report, around 2.5 million people in the U.S. suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the U.S. population is expected to rise to around 3.5 million by 2030. Similarly, data suggests that the incidence and prevalence of inflammatory bowel diseases [IBD] is still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020.

Request a sample to get extensive insights into the IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

COVID-19 Impact on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

The outbreak of COVID-19 has had a negative effect on the global IBD treatment market, as many governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Lockdowns in several countries, travel restrictions, and closure of the diagnostic centers led to a substantial decline in overall diagnostic procedures and treatments. According to two research letters published in JAMA Internal Medicine, there were 6,411 non-COVID-19 hospitalizations, including pediatric inflammatory bowel diseases, in 2019. This data is based on admissions to four hospitals in New York. However, the total admission in 2020 was 3,657 for the same conditions, while the overall decline of non-patients was around 40%. Players operating in the market witnessed a decline in revenue during the financial year 2020. For instance, Pfizer, Inc. registered a decline of -3.5% in revenue generated from its inflammation & immunology segment in 2020. Nevertheless, the market has seen a recovery from COVID-19 impact due to the easing of restrictions by various governments across the globe. Demand for drugs increased in 2021 due to the rise in diagnosis rate of diseases. Leading companies in the market reported an increase in revenue during 2021. Hence, the future IBD treatment market is anticipated to witness recovery at pre-pandemic levels.

Superior Efficacy, Safety, and Better Therapeutic Outcomes Augmenting Adoption of TNF Inhibitors

The TNF inhibitors segment is projected to lead the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. The segment's large market share can be ascribed to superior efficacy and safety of drugs in this class in the treatment of IBD, increase in adoption of biologics and biosimilars in countries in the West such as the U.K., France, Germany, and the U.S., and high cost of these drugs. Furthermore, rise in adoption of biologic drugs for the treatment of IBD and high clinical R&D budgets contributed to the TNF inhibitors segment's large share in 2021. TNF inhibitors are used as the second line of treatment when other medications do not work effectively to relieve symptoms of IBD. High adoption of TNF inhibitors owing to promising therapeutic results for the management of IBD, high per capita health care expenditure, and increase in number of hospitalizations can be ascribed to the TNF inhibitors segment's significant market share in 2021.

Request a custom report on IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

High Prevalence and Incidence of Ulcerative Colitis to Drive Demand for IBD Treatment

The ulcerative colitis segment accounted for the largest share of the global market in 2021. The trend is expected to continue during the forecast period. High prevalence and incidence of ulcerative colitis in Europe and North America, increase in awareness about the disease, and rise in number of hospitalization cases of ulcerative colitis are the key factors driving the ulcerative colitis segment. An article published on NCBI (2020) stated that ulcerative colitis has an incidence of 9 to 20 cases per 100,000 per year. Its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe. Similarly, in Canada, more than 104,000 people are living with ulcerative colitis and nearly 4,500 cases of ulcerative colitis are diagnosed every year. Furthermore, a recent report suggests that 600,000 to 900,000 people in the U.S. have ulcerative colitis.

Availability of Wide Range of Drugs for IBD Propelling Retail Pharmacies Segment

The retail pharmacies segment dominated the global market in terms of market share in 2021 due to the rise in sale of biologic drugs through retail pharmacy chains in the U.S. Biologic drugs accounted for major share of the IBD treatment market in the U.S. in 2021. Easy availability of drugs such as corticosteroids, Aminosalicylates, and biologics at retail pharmacy stores and usage of these drugs, except biologics, as the first line of treatment is propelling the retail pharmacies segment. Moreover, retail pharmacies are considered the first point of contact for self-medication. In 2019, India had more than 800,000 pharmacies; retail pharmacies are still the dominant medical distribution channel. Hence, presence of a large existing base of retail pharmacy stores in countries such as India, China, the U.S., and Canada is likely to augment the retail pharmacies segment during the forecast period.

Regional Outlook of Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2021. It is projected to gain major market share by the end of 2031. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of ulcerative colitis and Crohn’s disease in the U.S. and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors. Additionally, strong product pipeline of key players is projected to drive the global IBD (ulcerative colitis and Crohn’s disease) treatment market in the region.

Asia Pacific is projected to be the fastest growing market for IBD (ulcerative colitis and Crohn’s disease) treatment during the forecast period. Japan dominated the IBD treatment market in the region in 2021. The IBD (ulcerative colitis and Crohn’s disease) treatment market in China is anticipated to grow at a high CAGR during the forecast period. The IBD (ulcerative colitis and Crohn’s disease) treatment market in Latin America and Middle East & Africa is likely to expand at a decent CAGR during the forecast period due to the increase in IBD patient pool and rise in focus of manufacturers on the development of novel therapeutics.

Key Developments in Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

  • In May 2021, Bristol Myers Squibb announced that the Food and Drug Administration (FDA) approved Zeposia (ozanimod) for the treatment of moderate to severe active ulcerative colitis in adults
  • In September 2019, Janssen Biotech, Inc.’s product, STELARA, was approved for the treatment of moderate to severe active ulcerative colitis in the European Union
  • In April 2019, Salix Pharmaceuticals entered into an exclusive license agreement with Mitsubishi Tanabe Pharma to commercialize and develop late stage investigational S1P modulator for the treatment of inflammatory bowel disease
  • In October 2018, Allergan launched a personalized study approach for clinical research programs in inflammatory bowel disease. These programs would evaluate the efficacy and safety of brazikumab and the potential correlation between biomarkers and the patient outcomes with brazikumab.

Each of these players has been profiled in the IBD (ulcerative colitis & Crohn’s disease) treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Snapshot

Attribute Detail
Market Size Value in 2021 US$ 17.3 Bn
Market Forecast Value in 2031 More than US$ 34.22 Bn
Compound Annual Growth Rate (CAGR) 6.8%
Forecast Period 2022-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape
  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug Class
    • TNF Inhibitors
    • Aminosalicylates
    • Integrin Antagonists
    • Corticosteroids
    • Others
  • Disease Indication
    • Ulcerative Colitis
    • Crohn’s Disease
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Pfizer, Inc.
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • Health Companies, Inc.
  • Allergan plc
  • Takeda Pharmaceutical Company Limited
  • AbbVie, Inc.
  • Novartis AG
  • UCB, Inc.
  • Biogen, Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global IBD (ulcerative colitis & Crohn’s disease) treatment market in 2021?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market was valued at US$ 17.3 Bn in 2021

How big will be the global IBD (ulcerative colitis & Crohn’s disease) treatment market in 2031?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market is projected to reach more than US$ 34.22 Bn by 2031

What will be the CAGR of the global IBD (ulcerative colitis & Crohn’s disease) treatment market during the forecast period (2022–2031)?

The global IBD (ulcerative colitis & Crohn’s disease) treatment market is anticipated to grow at a CAGR of 6.8% from 2022 to 2031

Which are the prominent trends that affect market growth?

Increase in incidence of ulcerative colitis and Crohn’s disease is driving the global IBD (ulcerative colitis & Crohn’s disease) treatment market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global IBD (ulcerative colitis & Crohn’s disease) treatment market during the forecast period

Who are the prominent players in the global IBD (ulcerative colitis & Crohn’s disease) treatment market?

Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Health Companies, Inc., Allergan plc., Takeda Pharmaceutical Company Limited, AbbVie, Inc., Novartis AG, and UCB, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market

    4. Market Overview

        4.1. Overview

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunities

        4.3. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Industry Events

        5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Drug Class, 2017-2031

            6.3.1. TNF Inhibitors

            6.3.2. Aminosalicylates

            6.3.3. Integrin Antagonists

            6.3.4. Corticosteroids

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Drug Class

    7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Disease Indication

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Indication, 2017-2031

            7.3.1. Ulcerative Colitis

            7.3.2. Crohn’s Disease

        7.4. Market Attractiveness Analysis, by Disease Indication

    8. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017-2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug Class, 2017-2031

            10.2.1. TNF Inhibitors

            10.2.2. Aminosalicylates

            10.2.3. Integrin Antagonists

            10.2.4. Corticosteroids

            10.2.5. Others

        10.3. Market Value Forecast, by Disease Indication, 2017-2031

            10.3.1. Ulcerative Colitis

            10.3.2. Crohn’s Disease

        10.4. Market Value Forecast, by Distribution Channel, 2017-2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. Market Value Forecast, by Country, 2017-2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Drug Class

            10.6.2. By Disease Indication

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017-2031

            11.2.1. TNF Inhibitors

            11.2.2. Aminosalicylates

            11.2.3. Integrin Antagonists

            11.2.4. Corticosteroids

            11.2.5. Others

        11.3. Market Value Forecast, by Disease Indication, 2017-2031

            11.3.1. Ulcerative Colitis

            11.3.2. Crohn’s Disease

        11.4. Market Value Forecast, by Distribution Channel, 2017-2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Drug Class

            11.6.2. By Disease Indication

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017-2031

            12.2.1. TNF Inhibitors

            12.2.2. Aminosalicylates

            12.2.3. Integrin Antagonists

            12.2.4. Corticosteroids

            12.2.5. Others

        12.3. Market Value Forecast, by Disease Indication, 2017-2031

            12.3.1. Ulcerative Colitis

            12.3.2. Crohn’s Disease

        12.4. Market Value Forecast, by Distribution Channel, 2017-2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.5.1. China

            12.5.2. India

            12.5.3. Japan

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Drug Class

            12.6.2. By Disease Indication

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017-2031

            13.2.1. TNF Inhibitors

            13.2.2. Aminosalicylates

            13.2.3. Integrin Antagonists

            13.2.4. Corticosteroids

            13.2.5. Others

        13.3. Market Value Forecast, by Disease Indication, 2017-2031

            13.3.1. Ulcerative Colitis

            13.3.2. Crohn’s Disease

        13.4. Market Value Forecast, by Distribution Channel, 2017-2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Drug Class

            13.6.2. By Disease Indication

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Drug Class, 2017-2031

            14.2.1. TNF Inhibitors

            14.2.2. Aminosalicylates

            14.2.3. Integrin Antagonists

            14.2.4. Corticosteroids

            14.2.5. Others

        14.3. Market Value Forecast, by Disease Indication, 2017-2031

            14.3.1. Ulcerative Colitis

            14.3.2. Crohn’s Disease

        14.4. Market Value Forecast, by Distribution Channel, 2017-2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Drug Class

            14.6.2. By Disease Indication

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. AbbVie, Inc.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Allergan plc

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Bausch Health Companies, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Biogen, Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Bristol-Myers Squibb Company

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Celltrion Healthcare Co., Ltd.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Janssen Biotech, Inc. (Johnson & Johnson

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Novartis AG

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Pfizer, Inc.

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

                15.3.9.5. Strategic Overview

            15.3.10. Takeda Pharmaceutical Company Limited

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

                15.3.10.5. Strategic Overview

            15.3.11. UCB, Inc.

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

            15.3.12. Other Prominent Players

    List of Tables

    Table 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 02: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 03: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 04: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 05: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 06: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 07: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 08: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 09: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 10: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 11: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 12: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 13: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 14: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 15: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 16: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 17: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 18: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 19: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 20: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 21: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 23: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017-2031

    Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    Figure 01: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02: Market Value Share, by Drug Class, 2021

    Figure 03: Market Value Share, by Disease Indication, 2021

    Figure 04: Market Value Share, by Distribution Channel, 2021

    Figure 05: Market Value Share, by Region, 2021

    Figure 06: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

    Figure 07: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031

    Figure 08: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by TNF Inhibitors, 2017-2031

    Figure 09: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Aminosalicylates, 2017-2031

    Figure 10: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Integrin Antagonists, 2017-2031

    Figure 11: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2031

    Figure 12: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017-2031

    Figure 13: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

    Figure 14: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031

    Figure 15: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ulcerative Colitis, 2017-2031

    Figure 16: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Crohn’s Disease, 2017-2031

    Figure 17: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

    Figure 18: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031

    Figure 19: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2031

    Figure 20: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2031

    Figure 21: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027

    Figure 22: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Region, 2021 and 2031

    Figure 23: Global IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Region, 2017-2031

    Figure 24: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 25: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country, 2021 and 2031

    Figure 26: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country, 2017-2031

    Figure 27: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 28: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

    Figure 29: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 30: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031

    Figure 31: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031

    Figure 32: North America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031

    Figure 33: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 34: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 35: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

    Figure 36: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 37: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

    Figure 38: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 39: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031

    Figure 40: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031

    Figure 41: Europe IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031

    Figure 42: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 43: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

    Figure 44: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 45: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

    Figure 46: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

    Figure 47: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

    Figure 48: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031

    Figure 49: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031

    Figure 50: Asia Pacific IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031

    Figure 51: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2031

    Figure 52: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 53: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025

    Figure 54: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 55: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Disease Indication, 2021 and 2031

    Figure 56: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 57: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Drug Class, 2017-2031

    Figure 58: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Disease Indication, 2017-2031

    Figure 59: Latin America IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017-2031

    Figure 60: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031

    Figure 61: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

    Figure 62: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Country/Sub-region, 2017-2031

    Figure 63: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Drug Class, 2021 and 2031

    Figure 64: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Disease Indication, 2021 and 2031

    Figure 65: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value Share, by Distribution Channel, 2021 and 2031

    Figure 66: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Drug Class, 2017-2031

    Figure 67: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Disease Indication, 2017-2031

    Figure 68: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Attractiveness, by Distribution Channel, 2017-2031

Copyright © Transparency Market Research, Inc. All Rights reserved